MLTXMoonLake Immunotherapeutics

HealthcareUSD
$15.61

The financials

MoonLake Immunotherapeutics by the numbers

MoonLake Immunotherapeutics income statement, Q1 2026 against the same quarter a year earlier
Income statementQ1 2026Q1 2025Change
Operating income−$70M−$47Mn/a
Net income−$70M−$40Mn/a
Diluted EPS−$0.98−$0.63n/a

Biotechnology

Ranks #128 of 145 by Smart Score

Compare peers
VIR-0.70%
Vir Biotechnology, Inc.
URGN-2.9%
UroGen Pharma Ltd.
FTRE+4.1%
Fortrea Holdings Inc.
ATAI+9.8%
AtaiBeckley Inc.
SRPT-4.1%
Sarepta Therapeutics, Inc.
AKTS+8.5%
Aktis Oncology, Inc.